Insider · CIK 0002069951
Elissa S. Cote
Files at VTGN (Vistagen Therapeutics, Inc.). First filing -, latest -.
Elissa S. Cote files SEC Form 4 as officer at VTGN (Vistagen Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Elissa S. Cote has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 7, 2026 | VTGN Vistagen Therapeutics, Inc. | AGrant or award Incentive Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Apr 9, 2026 |
| Jun 23, 2025 | VTGN Vistagen Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Jun 25, 2025 |
Questions about Elissa S. Cote
Answered from the filings on this page, as of the latest one.
Is Elissa S. Cote buying or selling?
Elissa S. Cote has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Elissa S. Cote's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Elissa S. Cote has 0.
Where does Elissa S. Cote file Form 4?
Elissa S. Cote has filed Form 4 at VTGN (Vistagen Therapeutics, Inc.) as Chief Corp Development Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.